Overview

Effects of Dexmedetomidine/Lidocaine/Intrathecal Morphine on Cancer Metastasis Biomarker After Colorectal Surgery

Status:
Not yet recruiting

Trial end date:
2024-03-01

Target enrollment:
0

Participant gender:
All

Summary

This is a prospective randomized controlled trial. Investigators aimed to compare the effect of three different anesthetic adjuvants (continuous infusion of lidocaine or dexmedetomidine, intrathecal morphine injection) on the biomarker for cancer recurrence and metastasis. Patients undergoing elective colorectal cancer surgery will be randomly allocated to three parallel arms and the biomarkers for cancer recurrence and metastasis, inflammation, and immune response will be compared. And we will compare the clinical outcomes in the three method.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Samsung Medical Center

Collaborator:

Korea Institute of Science and Technology

Treatments:

Dexmedetomidine
Lidocaine
Morphine

Criteria

Inclusion Criteria:

- Patients who were scheduled for elective colorectal cancer surgery American Society of
Anesthesiologists physical status of I-III

Exclusion Criteria:

- Atrioventricular conduction disorder

- Having Bradycardia (<50 bpm)

- Severe pulmonary dysfunction in pulmonary function test

- High risk for cardiovascular complications(expected postoperative event >5%)

- Allergy or hypersensitivity reaction to each adjuvant.

- History or risk factors for Malignant hyperthermia

- Body mass index >40 kg/m2